Androgen-deprivation therapy is associated with Alzheimer's disease

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Androgen-deprivation therapy (ADT) in patients with prostate cancer is associated with the development of Alzheimer's disease.

Why this matters

  • Clinicians considering treating prostate cancer with ADT may also want to consider the patient's risk for Alzheimer's disease as well.

Key results

  • Patients were divided into 4 groups: non-ADT (patients who never received ADT; n=8401), patients who received injections for at least 3 mo (injection cohort [INJ]; n=1008), patients who received oral therapy for at least 3 mo (n=9963), and patients who received injections and oral medication (n=4905).
  • Non-ADT incidence of AD was 2.78/1000 person-years and 5.66/1000 in the ADT cohort.
  • Age-adjusted Cox proportional hazards regression model showed that the ADT cohort was 1.84 times more likely to develop dementia than the non-ADT group.

Study design

  • Retrospective analysis of data from 24,360 patients with prostate cancer who were and were not receiving ADT for 4 y and analyzed the relationship between ADT and the development of dementia.
  • Funding: None disclosed.

Limitations

  • Retrospective study design.
  • Non-ADT patients were generally younger than ADT patients.